Delfi (SGX:P34) Strong Profits May Be Masking Some Underlying Issues

Delfi Limited's (SGX:P34) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see. SG

Simply Wall StApr 12 18:43 ET

Delfi's Earnings Margins May Face Minimal Pressure From High Cocoa Prices -- Market Talk

0713 GMT - Delfi's earnings margins may face minimal pressure from high prices of its key ingredient cocoa, RHB Research analyst Alfie Yeo says in a research report. The Singapore-listed chocolate con

WSJApr 11 03:13 ET

Delfi (SGX:P34) Is Due To Pay A Dividend Of $0.0302

Yahoo FinanceApr 5 18:38 ET

Delfi Limited Announces Board Leadership Transition

TipRanksApr 5 06:47 ET

DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting

DELFI Diagnostics, Inc. (PRNewsfoto/DELFI Diagnostics) FirstLook Lung is a new blood test that offers a convenient, accessible, and personalized approach to enhance lung cancer screening. Firs

PR NewswireApr 1 09:00 ET

Delfi Faces Earnings Hit From Higher Raw Material Prices -- Market Talk

0415 GMT - Delfi faces an earnings hit from higher raw material prices, RHB Research analyst Alfie Yeo says, noting that the Singapore-listed company's 2023 revenue growth and operating margins missed

WSJMar 19 00:15 ET